Αρχειοθήκη ιστολογίου

Τρίτη 24 Οκτωβρίου 2017

A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors

Conditions:   Melanoma;   Non-Small Cell Lung Cancer;   Bladder Cancer;   Colorectal Cancer;   Triple Negative Breast Cancer;   Renal Cancer;   Head and Neck Cancer;   Other Solid Cancers
Interventions:   Drug: RO7198457;   Drug: Atezolizumab
Sponsors:   Genentech, Inc.;   Biontech RNA Pharmaceuticals GmbH
Recruiting

http://ift.tt/2yLsbLN

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου